S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns

uniQure (QURE) Stock Price, News & Analysis

$5.41
+0.09 (+1.69%)
(As of 03/27/2024 ET)
Today's Range
$5.24
$5.45
50-Day Range
$4.82
$6.75
52-Week Range
$4.76
$22.48
Volume
600,446 shs
Average Volume
1.38 million shs
Market Capitalization
$258.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.00

uniQure MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
491.5% Upside
$32.00 Price Target
Short Interest
Bearish
12.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$339,845 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.49) to ($4.17) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.08 out of 5 stars

Medical Sector

605th out of 939 stocks

Pharmaceutical Preparations Industry

282nd out of 432 stocks

QURE stock logo

About uniQure Stock (NASDAQ:QURE)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

QURE Stock Price History

QURE Stock News Headlines

uniQure: The AMT-130 Readout
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
5 unique date ideas in NW Arkansas - Axios
Amazon has a unique inflation problem - Reuters
See More Headlines
Receive QURE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:QURE
Employees
480
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.00
High Stock Price Target
$56.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+491.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-308,480,000.00
Net Margins
-1,947.09%
Pretax Margin
-1,934.97%

Debt

Sales & Book Value

Annual Sales
$15.84 million
Book Value
$4.34 per share

Miscellaneous

Free Float
45,901,000
Market Cap
$258.81 million
Optionable
Optionable
Beta
0.97
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives


QURE Stock Analysis - Frequently Asked Questions

Should I buy or sell uniQure stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" QURE shares.
View QURE analyst ratings
or view top-rated stocks.

What is uniQure's stock price target for 2024?

7 brokerages have issued 12 month target prices for uniQure's stock. Their QURE share price targets range from $7.00 to $56.00. On average, they expect the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 491.5% from the stock's current price.
View analysts price targets for QURE
or view top-rated stocks among Wall Street analysts.

How have QURE shares performed in 2024?

uniQure's stock was trading at $6.77 at the start of the year. Since then, QURE stock has decreased by 20.1% and is now trading at $5.41.
View the best growth stocks for 2024 here
.

When is uniQure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our QURE earnings forecast
.

How were uniQure's earnings last quarter?

uniQure (NASDAQ:QURE) issued its earnings results on Wednesday, February, 28th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.54) by $0.01. The biotechnology company had revenue of $6.69 million for the quarter, compared to analysts' expectations of $3.20 million. uniQure had a negative trailing twelve-month return on equity of 99.31% and a negative net margin of 1,947.09%.

What ETF holds uniQure's stock?

Global X Genomics & Biotechnology ETF holds 100,751 shares of QURE stock, representing 0.69% of its portfolio.

What is Matthew Kapusta's approval rating as uniQure's CEO?

8 employees have rated uniQure Chief Executive Officer Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among the company's employees.

What other stocks do shareholders of uniQure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Block (SQ) and bluebird bio (BLUE).

Who are uniQure's major shareholders?

uniQure's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vestal Point Capital LP (8.21%), Schroder Investment Management Group (2.60%), Vanguard Group Inc. (2.01%), Vanguard Group Inc. (2.01%), Point72 Asset Management L.P. (1.95%) and BNP Paribas Financial Markets (1.48%). Insiders that own company stock include Alexander Edward Kuta III, Christian Klemt, Leonard E Post, Matthew C Kapusta, Paula Soteropoulos, Pierre Caloz, Rachelle Suzanne Jacques, Ricardo Dolmetsch and Robert Gut.
View institutional ownership trends
.

How do I buy shares of uniQure?

Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:QURE) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners